Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
David Lorente(Hospital Universitari i Politècnic La Fe), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Leon W.M.M. Terstappen(Düsseldorf University Hospital), Martin Fleisher(Lamont-Doherty Earth Observatory), Daniel C. Danila, Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), Mateus Crespo(Institute of Cancer Research), Thian Kheoh(Janssen (United States)), Susana Miranda(Royal Marsden NHS Foundation Trust), Penny Flohr(Royal Marsden NHS Foundation Trust), David Olmos(Spanish National Cancer Research Centre), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Ines Figueiredo(Institute of Cancer Research), Arturo Molina(Janssen (United States)), Kurt Baeten(Janssen (Belgium)), Robert McCormack(Menlo School), George Seed(Institute of Cancer Research)
Cited by 154
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k